Yew Bio-Pharm Group, Inc. Finite-Lived Intangible Asset, Expected Amortization, Year Five
Yew Bio-Pharm Group, Inc. had Finite-Lived Intangible Asset, Expected Amortization, Year Five of $2.91 million as of 2020-12-31, per its 10-K filed 2021-03-30.
Discontinued › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, after Accumulated Amortization, Estimated Amortization Expense, Fiscal Year Maturity
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive · last filed 2021-03-30
- 2020-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $2.91M.
- 2019-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $1.74M.
- 2018-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $4.62M.
- 2017-12-31: Finite-Lived Intangible Asset, Expected Amortization, Year Five $285.95K.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Year Five |
|---|---|
| 2020-12-31 | $2.91M 10-K · filed 2021-03-30 |
| 2019-12-31 | $1.74M 10-K · filed 2020-05-14 |
| 2018-12-31 | $4.62M 10-K · filed 2019-05-07 |
| 2017-12-31 | $285.95K 10-K · filed 2018-04-02 |
| 2016-12-31 | $204.25K 10-K · filed 2017-03-31 |
| 2015-12-31 | $489.47K 10-K · filed 2016-03-30 |
| 2014-12-31 | $510.36K 10-K · filed 2015-03-31 |
| 2013-12-31 | $507.45K 10-K · filed 2014-03-31 |
| 2012-12-31 | $356.73K 10-K · filed 2013-04-11 |
| 2012-09-30 | $348.06K 10-Q · filed 2012-11-13 |
| 2012-06-30 | $344.59K 10-Q/A · filed 2012-09-14 |